Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068419 · ClinicalTrials.gov registry record · Phase 2
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
A Phase 2 study of Desmoid Tumor, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT00068419: Completed Phase 2 study of Desmoid Tumor, sponsored by Children's Oncology Group.
NCT00068419 is a Phase 2 study of Desmoid Tumor that has completed, run by Children's Oncology Group. The registered enrollment target is 70 participants, roughly in line with the 72-participant average among 4 other Desmoid Tumor trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00068419, a Phase 2 study of Desmoid Tumor, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well giving sulindac together with tamoxifen works in treating patients with desmoid tumor. Sulindac may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Hormone therapy using tamoxifen may fight cancer by blocking the use of estrogen. Combining sulindac with tamoxifen may kill more cancer cells.
Primary Outcome
Kaplan Meier estimate of failure free survival at 2 years, where failure free survival is defined as the time to relapse, progression, second malignancy, and death whichever occurs first.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG tamoxifen citrate
- DRUG sulindac
Study Locations (1)
California
- Children's Oncology Group - Monrovia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2004-02 |
| Est. Completion | 2010-04-26 |
| Phase | Phase 2 |
What the finished NCT00068419 record still lists
NCT00068419 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, roughly in line with the 72-participant average among 4 other Desmoid Tumor trials with a reported enrollment target.
The record links to 1 condition, with Desmoid Tumor appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00068419 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00068419 about?
NCT00068419 is a clinical study titled "Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor". This phase II trial is studying how well giving sulindac together with tamoxifen works in treating patients with desmoid tumor. Sulindac may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Hormone therapy using tamoxifen may fight cancer by blocking the use ...
What is the current status of trial NCT00068419?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2004-02. Estimated completion is 2010-04-26.
What conditions does trial NCT00068419 study?
This clinical trial studies the following conditions: Desmoid Tumor.
What interventions are being tested in trial NCT00068419?
The interventions under investigation include: laboratory biomarker analysis (OTHER), tamoxifen citrate (DRUG), sulindac (DRUG).
Who is sponsoring clinical trial NCT00068419?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00068419 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Desmoid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Cryoablation and Nirogacestat for Desmoid Tumor
RECRUITING · Phase 2
-
A Study of AL102 in Patients With Progressing Desmoid Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
COMPLETED · Phase 2
-
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia